Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
150.00
-3.25 (-2.12%)
At close: Jul 24, 2025, 4:00 PM
153.00
+3.00 (2.00%)
After-hours: Jul 24, 2025, 4:31 PM EDT

Company Description

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).

It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb.

Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech, Inc.
Krystal Biotech logo
CountryUnited States
Founded2015
IPO DateSep 20, 2017
IndustryBiotechnology
SectorHealthcare
Employees275
CEOKrish Krishnan

Contact Details

Address:
2100 Wharton Street, Suite 701
Pittsburgh, Pennsylvania 15203
United States
Phone412 586 5830
Websitekrystalbio.com

Stock Details

Ticker SymbolKRYS
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001711279
CUSIP Number501147102
ISIN NumberUS5011471027
Employer ID82-1080209
SIC Code2836

Key Executives

NamePosition
Krish S. Krishnan M.B.A., M.S.Founder, Chairman, President and Chief Executive Officer
Suma M. KrishnanFounder, President of Research & Development and Director
Kathryn A. Romano CPAExecutive Vice President and Chief Accounting Officer
John ThomasGeneral Counsel and Corporate Secretary
John KarakkalVice President of North American Sales and Marketing
Christine WilsonHead of U.S. Sales and Marketing
Dr. Stephane Paquette Ph.D.Vice President of Corporate Development
Josh SuskinSenior Director and Head of US Human Resources
Laurent GouxSenior Vice President and GM of Europe
David ChienSenior Vice President of Clinical Development

Latest SEC Filings

DateTypeTitle
Jul 9, 2025144Filing
Jul 9, 2025144Filing
Jul 9, 20258-KCurrent Report
Jun 2, 20258-KCurrent Report
May 19, 20258-KCurrent Report
May 13, 20258-KCurrent Report
May 6, 20258-KCurrent Report
May 6, 202510-QQuarterly Report
May 6, 20258-KCurrent Report
Apr 28, 20258-KCurrent Report